ABC | Volume 114, Nº1, January 2019

Original Article Leite et al. Carotid thickness in HIV-infected patients Arq Bras Cardiol. 2020; 114(1):90-97 This is an open-access article distributed under the terms of the Creative Commons Attribution License 13. Haissman JM, Vestegaard LS, Sembuche S, Erikstrup C, Mmbando B, Mtullu S, et al. Plasma cytokine levels in Tanzanian HIV-1-infected adults and the effect of antiretroviral treatment. J Acquir Immune Defic Syndr. 2009;52(4):493-7. 14. Nguemaïm NF, Mbuagbaw J, Nkoat T, Alemnji G, Této G, Fanhi TC, et al. Serum lipid profile in highly active antiretroviral therapy-naive HIV-infected patients in Cameroon: a case-control study. HIV Med. 2010;11(6):353-9. 15. Kuti MA, AdesinaOa, AwoludeOa, Ogunbosi BO, Fayemiwo SA, Akinyemi JO, et al. Dyslipidemia in ART-naive HIV-infected persons in Nigeria- implications for care. J Int Assoc Provid AIDS Care. 2015;14(4):355-9. 16. Lorenz MW, Stephan C, Harmjanz A, Staszewski S, Buehler A, Bickel M, et al. Both long-termHIV infection and highly active antiretroviral therapy are independent risk factors for early carotid atherosclerosis. Atherosclerosis. 2008;196(2):720-6. 17. Falcão Mda C, Zírpoli JC, Albuquerque VM, Markman Filho B, Araújo NA, Falcão CA, et al. Association of biomarkers with atherosclerosis and risk for coronary artery disease in patients with HIV. Arq Bras Cardiol. 2012;99(5):971-8. 18. SsinabulyaI,KayimaJ,LongeneckerC,LuweddeM,SemitalaF,KambbuguA,et al.SubclinicalatherosclerosisamongHIV-infectedadultsattendingHIV/AIDScare attwo largeambulatoryHIVclinics inUganda.PLoSOne.2014;9(2):e89537. 97